Press Releases Archives | Page 79 of 117

LifePlus Stem Cells Delivers its First Allogeneic Mesenchymal Stem Cells for the Treatment of Arthritis

February 1, 2021 By BioInformant Team Leave a Comment

LifePlus Stem Cells, a provider of innovative stem cell advancements, specialising in regenerative rehabilitation announces their first injection of its umbilical cord-derived allogeneic mesenchymal stem cells. Using a unique and highly regulated manufacturing process, LifePlus Stem Cells is able to provide patients and clinicians with the world’s purest allogeneic mesenchymal stem cells – achieving purity levels of well over 80%.

Organicell Announces FDA Approval Of IND Application for the Use of Zofin™ In The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)

January 28, 2021 By Cade Hildreth, Founder & President Leave a Comment

Miami, FL (January 28^th, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD). [Read more…]

Applied StemCell Licenses Its TARGATT™ CHO Cell Technology for Biotherapeutics Development

January 26, 2021 By Cade Hildreth, Founder & President Leave a Comment

Applied StemCell Licenses Its TARGATT™ CHO Cell Technology to Twist Bioscience Corp. for Biotherapeutics Development

Milpitas, California, January 19th, 2021 — The multi-platform gene-editing company, Applied StemCell (ASC), announced a commercial license of its TARGATT™ CHO technology to Twist Bioscience (Twist), a global innovative synthetic biology company. Execution of the license agreement was based on the evaluation result of the TARGATT™ CHO cell platform by Twist to assess its suitability for Twist’s antibody discovery, library screening, and bioproduction process. [Read more…]

Results from phase 3 gene therapy trial for painful diabetic peripheral neuropathy has been published online by Clinical and Translational Science

January 20, 2021 By Cade Hildreth, Founder & President Leave a Comment

Results from the phase 3 gene therapy trial for painful diabetic peripheral neuropathy (DPN) have been published online by Clinical and Translational Science and suggest excellent safety profile and promising efficacy.

VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy.

[Read more…]

Jellagen launches JellaGel™, the first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix

January 15, 2021 By Cade Hildreth, Founder & President Leave a Comment

JellaGel™ uses Collagen Type 0 (marine sourced jellyfish) and is non-mammalian.
The hydrogel kit is easy to use (with Buffer and Crosslinker).
JellaGel™ can be used at room temperature.

Jellagen® Limited, a biotechnology company manufacturing high value Collagen Type 0 derived from jellyfish, announce the launch of their JellaGel™ Hydrogel. 3-dimensaional Hydrogels allow cells to grow and interact with all of their surroundings which makes a huge difference. [Read more…]

Applied StemCell Licenses Its TARGATT™ CHO Cell Technology to Twist Bioscience Corp. for Biotherapeutics Development

Results from the phase 3 gene therapy trial for painful diabetic peripheral neuropathy (DPN) have been published online by Clinical and Translational Science and suggest excellent safety profile and promising efficacy.

VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy.

[Read more…]

JellaGel™ uses Collagen Type 0 (marine sourced jellyfish) and is non-mammalian.

The hydrogel kit is easy to use (with Buffer and Crosslinker).

JellaGel™ can be used at room temperature.